Adalimumab, ixekizumab, Humira® No. 1 Drug Linked to $5.1 B Increase in Medical Spending

A analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported outcomes (PROs) in patients with moderate‐to‐severe chronic plaque psoriasis (PsO), rheumatoid arthritis (RA), and psoriatic arthritis (PsA) observed similar outcomes between the two treatments.

ADACCESS and ADMYRA were both phase III studies, with the former including 465 patients with PsO and the latter including 353 patients with RA (ADACCESS also included patients with PsA). The studies compared the biosimilar versus reference adalimumab regarding efficacy, safety, and immunogenicity. In ADACCESS, beginning at week 17, a third of patients underwent four treatment switches between study treatments. In ADMYRA, beginning at week 24, the entire cohort was switched from reference adalimumab to SDZ-ADL. ADACCESS evaluated patients’ PROs using the Dermatology Life Quality Index (DLQI) and EuroQol five-dimension health status questionnaire (EQ-5D-5L), ADMYRA used the Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-Fatigue) score, and both studies used the Health Assessment Questionnaire–Disability Index (HAQ-DI).

In ADACCESS, both groups experienced comparable decreases in DLQI from baseline to week 17; the mean percent reduction in the SDZ-ADL group was 64.5% (standard deviation [SD], 80.3%), and in the adalimumab group, 70.6% (SD, 41.7%); outcomes remained similar at the week 51 switch. In the PsA group in the ADACCESS study, decreases were observed in mean HAQ-DI scores from baseline in both treatment groups, with no significant between-group differences at week 17 or after switching at week 51. In ADMYRA, there were no significant between-group differences in attaining normal-range HAQ-DI at week 24 or after switching at week 48. Both groups presented increases in mean FACIT-Fatigue scores.

The study was published in BioDrugs.

“Treatment with SDZ-ADL and reference adalimumab resulted in comparable improvements in PROs as well as quality of life scores across the three diseases, PsO, PsA, and RA. Switching between SDZ-ADL and reference adalimumab had no negative impact on PROs across the reported period,” the study authors concluded.

Credit: Original article published here.